

13th January 2026

| | |
|--|--|
| BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 Scrip Code: BSE – AJANTPHARM 532331 | National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Scrip Code: NSE AJANTPHARM EQ |
|--|--|

Sub.: Formation of Subsidiary**Ref.: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015**

Dear Sirs/Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform you that a wholly owned subsidiary of the Company has been incorporated in Ireland as “Ajanta Pharma Ireland Ltd.”

The relevant details as required under the SEBI Listing Regulations are enclosed as Annexure - A.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

Gaurang Shah*Sr. VP – Legal & Company Secretary*

Annexure A

| Sr. No. | Particulars | Details |
|---------|---|---|
| 1 | Name of the target entity, details in brief such as size, turnover etc. | The name of the Wholly Owned Subsidiary is “Ajanta Pharma Ireland Ltd.” incorporated in Ireland. Size/Turnover: Not applicable |
| 2 | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length” | Not Applicable |
| 3 | Industry to which the entity being acquired belongs | Pharmaceutical |
| 4 | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity | The Wholly Owned Subsidiary has been incorporated in Ireland for the purpose of carrying on the business of pharmaceutical products. |
| 5 | Brief details of any governmental or regulatory approvals required for the acquisition | Not Applicable |
| 6 | Indicative time period for completion of the acquisition | Not Applicable |
| 7 | Consideration -whether cash consideration or share swap or any other form and details of the same | Not Applicable |
| 8 | Cost of acquisition and/or the price at which the shares are acquired | Not Applicable |
| 9 | Percentage of shareholding / control acquired and/or number of shares acquired | The Company is a Wholly Owned Subsidiary |
| 10 | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) | History and Turnover: Newly Incorporated Company |